1. Screening Libraries
  2. Anti-Hepatitis C Virus Compound Library

Anti-Hepatitis C Virus Compound Library

Cat. No.: HY-L073
Library Contents: XLSX PDF SDF

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).

HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 160 compounds with identified and poten

MCE Anti-Hepatitis C Virus Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 159 compounds supplied in 10 mM solution and 1 compounds supplied in 2 mM solution.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.

  • 96-well Plate with Peelable Foil Seal
  • 96-well Storage Tubes with Rack
Size (Pre-dissolved Solution or Solid) Price Stock
30 μL/well Solution

10 mM and 2 mM
Pre-dissolved Solution

Get quote In-stock
50 μL/well Solution

10 mM and 2 mM
Pre-dissolved Solution

Get quote In-stock
100 μL/well Solution

10 mM and 2 mM
Pre-dissolved Solution

Get quote In-stock
2 × 100 μL/well Solution

10 mM and 2 mM
Pre-dissolved Solution

Get quote In-stock

Please contact us at

[email protected]

Top Publications Citing Use of Products
  • Description

  • Product Details

  • Composition

  • Documentation

Description
& Advantages

•   A unique collection of 160 bioactive anti-hepatitis C virus compounds for high throughput screening (HTS) and high content screening (HCS).

•   Targets include NS3, NS4A, NS5A, RNA-dependent RNA-polymerases, EGFR, etc.

•   A useful tool for the discovery of anti-HCV drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Detailed compound information with structure, IC50, and brief introduction.

•   Validated NMR and HPLC to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

Product Details
Formulation:
A collection of 160 compounds with anti-HCV activity supplied as pre-dissolved Solutions or Solid
Solution: 159 compounds supplied in 10 mM solution, 1 compounds supplied in 2 mM solution.
Container:
96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:
-80°C
Shipping:
Blue ice
Composition

Anti-Hepatitis C Virus Compound Library

Source: MedChem Express

Documentation

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Container *

    Remarks

    Inquiry Online

    Inquiry Information

    Product Name:
    Anti-Hepatitis C Virus Compound Library
    Cat. No.:
    HY-L073
    Quantity:
    MCE Japan Authorized Agent:

    Request SDF File

    Please enter your email address. We will send your requested SDF file to you as soon as possible.

    • 96-well Plate with Peelable Foil Seal
    • 96-well Storage Tubes with Rack